Gut microbiome diversity loss in patients who receive antibiotics Other
Conditions
Interventions
Patients are asked to take one capsule per day of PBPGP22 or a placebo alongside their prescribed antibiotic for approximately 20 days (variability arises because the intervention is given alongside a
Sponsors
Postbiotics Plus Research LLC
Eligibility
Sex/Gender
All
Age
18 Years to 110 Years
Inclusion criteria
Inclusion criteria: 1. Otherwise healthy adults with a body mass index (BMI) (18-28 kg/m²) 2. Patients prescribed a course of antibiotics for 5 days or longer 3. Patients have not had another course of antibiotics in the past 6 months 4. Patients are willing to cease taking any other supplements or probiotics
Exclusion criteria
Exclusion criteria: 1. History of regular and severe constipation, diarrhea, inflammatory bowel disorder or Crohn’s disease 2. Usually experience severe diarrhea (e.g. for more than 3 days) following antibiotic treatment 3. Have a compromised immune system 4. Are taking any immune modulators 5. Have an autoimmune disorder 6. Are diabetic 7. Are taking blood pressure medication 8. Have allergies to the ingredients of T or C 9. Are pregnant 10. Are nursing
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bacterial alpha diversity measured by 16S rRNA gene sequencing of DNA in stool samples collected at three timepoints relative to the antibiotic treatment course and quantified by the inverse Simpson diversity index: on the final day of antibiotics, the first day after completing the antibiotics course, and the second day after completing the antibiotics course | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Bacterial alpha diversity measured by 16S rRNA gene sequencing of DNA in stool samples collected at three timepoints relative to the antibiotic treatment course and quantified by the Shannon diversity index: on the final day of antibiotics, the first day after completing the antibiotics course, and the second day after completing the antibiotics course 2. Bacterial alpha diversity measured by 16S rRNA gene sequencing of DNA in stool samples collected at two timepoints relative to the antibiotic treatment course and quantified by the inverse Simpson diversity index: on the third and tenth day after completing the antibiotics course 3. Blood inflammation markers measured using C-reactive protein test at the end of antibiotic treatment course | — |
Countries
United States of America
Contacts
Public ContactAubrey Levitt
Outcome results
None listed